Invivyd (NASDAQ:IVVD) Price Target Cut to $10.00 by Analysts at HC Wainwright

Invivyd (NASDAQ:IVVD) had its price objective lowered by equities researchers at HC Wainwright from $15.00 to $10.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Separately, EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th.

Invivyd Stock Performance

Shares of IVVD opened at $0.70 on Wednesday. The stock has a 50 day simple moving average of $0.97 and a 200 day simple moving average of $1.25. Invivyd has a 52-week low of $0.70 and a 52-week high of $5.20. The firm has a market capitalization of $83.71 million, a PE ratio of -0.36 and a beta of 0.65.

Hedge Funds Weigh In On Invivyd

Several large investors have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in Invivyd during the first quarter worth approximately $56,000. Vanguard Group Inc. grew its stake in Invivyd by 3.9% during the first quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock worth $11,594,000 after purchasing an additional 97,496 shares during the period. Acadian Asset Management LLC acquired a new stake in Invivyd during the first quarter worth approximately $905,000. Jacobs Levy Equity Management Inc. grew its stake in Invivyd by 21.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 435,338 shares of the company’s stock worth $1,933,000 after purchasing an additional 77,603 shares during the period. Finally, Tidal Investments LLC acquired a new stake in Invivyd during the first quarter worth approximately $126,000. 70.36% of the stock is currently owned by institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.